NEW YORK (GenomeWeb News) – Omicia said today that it intends to use funds from a recently closed $6.8 million Series A financing round led by Artis Ventures to expand its marketing reach and to optimize its whole-genome interpretation offering.

Other investors in the round included Acadia Woods Partners, Bay City Capital, Buchanan Investments, and Casdin Capital. As part of their investment, Tad Buchanan, principal of Buchanan Investments, and William Gerber from Bay City Capital will also join Omicia's board of directors, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.